Background: Several studies determined that autoimmune hemolytic anemia (AIHA) is a rare extraintestinal IBD manifestation, related to the underlying disease activity. However, evidence linking biologic therapy to AIHA is sparse.
Methods: This article reviews the evidence on the association of these clinical phenomena.
Results: There are two retrospective studies and a few case reports linking biologic therapies to AIHA.
Conclusions: While some autoimmune phenomenon triggered by our biologic therapies have been well recognized, we do not find the evidence associating these therapies to AIHA sufficiently compelling.
Keywords: Hemolytic anemia; IBD; vedolizumab.
© The Author(s) 2021. Published by Oxford University Press on behalf of Crohn\'s & Colitis Foundation.